Meta Pixel

News and Announcements

Vale Steven Peuschel OAM

  • Published November 20, 2017 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Vale Steven Peuschel OAM

It is with great sadness that we inform you of the passing of our colleague and friend, Steven Peuschel. Steve passed away on 7 November 2017 after a short but brave battle with late stage cancer. The entire 4Dx team sends our most heartfelt condolences and sympathy to his family and friends.

Steve was an extraordinary person who dedicated much of his life to improving healthcare. Over many years Steve worked with The Alfred hospital to raise awareness and desperately needed funds to address the significant shortcomings in the fields of respiratory medicine and organ transplant. Steve’s contribution to the development of new programs and protocols in these areas continues to provide positive health outcomes for many people.

Steve joined 4Dx on 5 January 2015 and as Executive Director and Senior Vice President, engaged with key opinion leaders and investors to ensure 4Dx had the knowledge, contacts and resources required take our technology to the clinic. Steve’s expertise, passion, positive attitude, and work ethic had an immediate and everlasting impact on 4Dx.

Steve will be profoundly missed not only by all at 4Dx, but also by our community as a whole. His humor, strength, character, tenacity, integrity, and charm will always be remembered, and his impact in the healthcare space will be felt for generations to come.

Sorely missed. Never Forgotten.

On behalf of Wholesale Investor, we would like to send our best wishes to the Peuschel Family. Steve was one of the most passionate and driven people we had the opportunity to work with. His dedication to the 4Dx mission inspired many and was created from his own lifelong challenges with health.

Thank you, Steve, for the opportunity to work with you and the 4Dx team. We hope that in your passing, we can assist in fulfilling the mission you were a part of creating.

Capital Insights
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t

The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.

Capital Insights
Following the Billions: Where the Hyperscalers are Betting on the Future

The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.

Join over 45,000+ sophisticated investors

Join Now